Polymorphisms of estrogen receptor alpha in prostate cancer

Molecular Carcinogenesis

Volumn 37, Issue 4, 2003, Pages 202-208

  Tanaka, Yuichiro ^a   Sasaki, Masahiro ^a,b   Kaneuchi, Masanori ^a,b   Shiina, Hiroaki ^a,c   Igawa, Mikio ^c   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOKKAIDO UNIVERSITY   (Japan)

^c SHIMANE UNIVERSITY   (Japan)

Author keywords

Estrogen receptor ; Polymorphism; Prostate cancer; Sequence specific PCR

Indexed keywords

ADENINE; CYTOSINE; DNA; ESTROGEN RECEPTOR ALPHA; GUANINE; THYMINE;

ARTICLE; CALCULATION; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; DNA SEQUENCE; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; INTRON; JAPAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; WILD TYPE;

BASE SEQUENCE; CODON; ESTROGEN RECEPTOR ALPHA; GENE FREQUENCY; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 0042568927     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10138     Document Type: Article

References (54)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: Current perspectives and future directions. Prostate 2002;52:213-235.
3. Matzkin H, Soloway MS. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 1992;21:309-314.
4. Schuurmans AL, Bolt J, Voorhorst MM, Blankenstein RA, Mulder E. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer 1988;42:917-922.
5. Sonnenschein C, Olea N, Pasanen ME, Soto AM. Negative controls of cell proliferation: Human prostate cancer cells and androgens. Cancer Res 1989;49:3474-3481.
6. Castagnetta LA, Miceli MD, Sorci CM, etal. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 1995;136:2309-2319.
7. Rhodes L, Ding VD, Kemp RK, et al. Estradiol causes a dose-dependent stimulation of prostate growth in castrated beagle dogs. Prostate 2000;44:8-18.
8. Leav I, Merk FB, Ofner P, et al. Bipotentiality of response to sex hormones by the prostate of castrated or hypophysectomized dogs. Direct effects of estrogen. Am J Pathol 1978;93:69-92.
9. Merk FB, Ofner P, Kwan PW, Leav I, Vena RL. Ultrastructural and biochemical expressions of divergent differentiation in prostates of castrated dogs treated with estrogen and androgen. Lab Invest 1982;47:437-450.
10. Levine AC, Kirschenbaum A, Droller M, Gabrilove JL. Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology, and serum prostate specific antigen in 4 men with benign prostatic hypertrophy. J Urol 1991;146:790-793.
11. Newbold RR, Bullock BC, McLachlan JA. Uterine adenocarcinoma in mice following developmental treatment with estrogens: A model for hormonal carcinogenesis. Cancer Res 1990;50:7677-7681.
12. Walker BE, Kurth LA. Pituitary tumors in mice exposed prenatally to diethylstilbestrol. Cancer Res 1993;53:1546-1549.
13. Jones LA, Pacillas-Verjan R. Transplantability and sex steroid hormone responsiveness of cervicovaginal tumors derived from female BALB/cCrgl mice neonatally treated with ovarian steroids. Cancer Res 1979;39:2591-2594.
14. Huseby RA. Demonstration of a direct carcinogenic effect of estradiol on Leydig cells of the mouse. Cancer Res 1980;40:1006-1013.
15. Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 1995;16:1311-1317.
16. Cavalieri EL, Devanesan P, Bosland MC, Badawi AF, Rogan EG. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: Implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 2002;23:329-333.
17. Suzuki K, Ito K, Suzuki T, Honma S, Yamanaka H. Synergistic effects of estrogen and androgen on the prostate: Effects of estrogen on androgen- and estrogen-receptors, BrdU uptake, immunohistochemical study of AR, and responses to antiandrogens. Prostate 1995;26:151-163.
18. Leav I, Merk FB, Kwan PW, Ho SM. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 1989;15:23-40.
19. Han X, Liehr JG, Bosland MC. Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 beta and testosterone. Carcinogenesis 1995;16:951-954.
20. Ito T, Tachibana M, Yamamoto S, Nakashima J, Murai M. Expression of estrogen receptor (ER-alpha and ER-beta) mRNA in human prostate cancer. Eur Urol 2001;40:557-563.
21. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 1999;155:641-647.
22. Leav I, Lau KM, Adams JY, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001;159:79-92.
23. Fujimura T, Takahashi S, Urano T, et al. Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun 2001;289:692-699.
24. Royuela M, de Miguel MP, Bethencourt FR, et al. Estrogen receptors alpha and beta in the normal, hyperplastic, and carcinomatous human prostate. J Endocrinol 2001;168:447-454.
25. Nativ O, Umehara T, Colvard DS, et al. Relationship between DNA ploidy and functional estrogen receptors in operable prostate cancer. Eur Urol 1997;32:96-99.
26. Latil A, Bieche I, Vidaud D, et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001;61:1919-1926.
27. Legrand M, Stucker I, Marez D, Sabbagh N, Lo-Guidice JM, Broly F. Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility. Carcinogenesis 1996;17:2267-2269.
28. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997;52:1034-1040.
29. Kitagawa K, Kunugita N, Kitagawa M, Kawamoto T. CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 2001;276:17830-17835.
30. Zhang ZY, Fasco MJ, Huang L, Guengerich FP, Kaminsky LS. Characterization of purified human recombinant cytochrome P450 1A1-Ile462 and -Val462: Assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996;56:3926-3933.
31. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999;20:1607-1613.
32. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-3444.
33. Hengstler JG, Arand M, Herrero ME, Oesch F. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase, and sulfotransferases: Influence on cancer susceptibility. Recent Results Cancer Res 1998;154:47-85.
34. Thompson PA, Ambrosone C. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 2000;27:125-134. Review.
35. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002;12:182-196.
36. Roodi N, Bailey LR, Kao WY, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995;87:446-451.
37. Yaich L, Dupont WD, Cavener DR, Parl FF. Analysis of the Pvull restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 1992;52:77-83.
38. Iwase H, Greenman JM, Barnes DM, Hodgson S, Bobrow L, Mathew CG. Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. Cancer Lett 1996;108:179-184.
39. Curran JE, Lea RA, Rutherford S, Weinstein SR, Griffiths LR. Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer. Int J Cancer 2001;95:271-275.
40. Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S, Dahiya R. Single nucleotide polymorphisms of estrogen receptor alpha in human renal cell carcinoma. Biochem Biophys Res Commun 2002;296:1200-1206.
41. Speer G, Cseh K, Winkler G, et al. Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers. Eur J Cancer 2001;37:1463-1468.
42. Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A, Baron JA. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis 2000;21:623-627.
43. Modugno F, Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and the androgen and estrogen receptors: Toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001;7:3092-3096.
44. Ponglikitmongkol M, Green S, Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J 1988;7:3385-3388.
45. Rollerova E, Urbancikova M. Intracellular estrogen receptors, their characterization and function (review). Endocr Regul 2000;34:203-218.
46. Goldstein JS, Sites CK. Selective modulation of sex steroids. Ageing Res Rev 2002;1:17-28.
47. Stack G, Kumar V, Green S, et al. Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells. Cancer Treat Res 1988;40:185-206.
48. White R, Parker MG. Molecular mechanisms of steroid hormone action. Endocr Relat Cancer 1998;5:1-14.
49. Lewin B. Genes. New York, NY: Oxford University Press; 1997. p 700.
50. Lehrer S, Rabin J, Kalir T, Schachter BS. Estrogen receptor variant and hypertension in women. Hypertension 1993;21:439-441.
51. Lehrer S, Sanchez M, Song HK, et al. Oestrogen receptor Bregion polymorphism and spontaneous abortion in women with breast cancer. Lancet 1990;335:622-624.
52. Habuchi T, Liqing Z, Suzuki T, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000;60:5710-5713.
53. Wu WJ, Kakehi Y, Habuchi T, et al. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res 1995;86:730-736.
54. Beilin J, Harewood L, Frydenberg M, et al. A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects. Cancer 2001;92:941-949.